[
  {
    "ts": "2026-02-11T00:17:32+00:00",
    "headline": "How Recent Analyst Shifts Are Rewriting The Story For Johnson & Johnson (NYSE:JNJ)",
    "summary": "What Is Driving the New Fair Value Estimate for Johnson & Johnson? The fair value estimate for Johnson & Johnson has shifted from about US$224.09 to roughly US$231.25 per share, and the revenue growth assumption has moved from about 5.81% to roughly 6.04%, with a small change in the discount rate from 6.96% to 6.98% to reflect a slightly different view of risk. Recent Street research has tilted more positive, with several firms raising price targets and one new initiation that calls the stock...",
    "url": "https://finance.yahoo.com/news/recent-analyst-shifts-rewriting-story-001732017.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "4da9c845-b723-3f3d-8e0e-c2a9df4ffb0d",
      "content": {
        "id": "4da9c845-b723-3f3d-8e0e-c2a9df4ffb0d",
        "contentType": "STORY",
        "title": "How Recent Analyst Shifts Are Rewriting The Story For Johnson & Johnson (NYSE:JNJ)",
        "description": "",
        "summary": "What Is Driving the New Fair Value Estimate for Johnson & Johnson? The fair value estimate for Johnson & Johnson has shifted from about US$224.09 to roughly US$231.25 per share, and the revenue growth assumption has moved from about 5.81% to roughly 6.04%, with a small change in the discount rate from 6.96% to 6.98% to reflect a slightly different view of risk. Recent Street research has tilted more positive, with several firms raising price targets and one new initiation that calls the stock...",
        "pubDate": "2026-02-11T00:17:32Z",
        "displayTime": "2026-02-11T00:17:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/recent-analyst-shifts-rewriting-story-001732017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/recent-analyst-shifts-rewriting-story-001732017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T03:05:00+00:00",
    "headline": "Is Johnson & Johnson a Buy, Sell, or Hold in 2026?",
    "summary": "This reliable dividend payer may be just what the doctor ordered.",
    "url": "https://www.fool.com/investing/2026/02/10/is-johnson-johnson-a-buy-sell-or-hold-in-2026/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "6e334715-1490-3c85-a6e8-575c023aa24d",
      "content": {
        "id": "6e334715-1490-3c85-a6e8-575c023aa24d",
        "contentType": "STORY",
        "title": "Is Johnson & Johnson a Buy, Sell, or Hold in 2026?",
        "description": "",
        "summary": "This reliable dividend payer may be just what the doctor ordered.",
        "pubDate": "2026-02-11T03:05:00Z",
        "displayTime": "2026-02-11T03:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3a6bcc292cf39aa549c6cbedc0ab1498",
          "originalWidth": 1400,
          "originalHeight": 828,
          "caption": "Patient in consultation with a pharmacist.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1rgSOIULJZXdQP.9qPqFqw--~B/aD04Mjg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/3a6bcc292cf39aa549c6cbedc0ab1498.cf.webp",
              "width": 1400,
              "height": 828,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oZ1FZVtLFA8kCNrzyXjVdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3a6bcc292cf39aa549c6cbedc0ab1498.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/10/is-johnson-johnson-a-buy-sell-or-hold-in-2026/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-buy-sell-hold-030500733.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T08:30:00+00:00",
    "headline": "[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cell Therapy Raw Materials Market size & share revenue was valued at approximately USD 5.2 Billion in 2025 and is expected to reach USD 6.1 Billion in 2026 and is expected to reach around USD 29.3 Billion by 2035, at a CAGR of 18.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientifi",
    "url": "https://finance.yahoo.com/news/latest-global-cell-therapy-raw-083000732.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "2d9d4e5a-57d6-3ebf-9253-c5ff525668f4",
      "content": {
        "id": "2d9d4e5a-57d6-3ebf-9253-c5ff525668f4",
        "contentType": "STORY",
        "title": "[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
        "description": "",
        "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cell Therapy Raw Materials Market size & share revenue was valued at approximately USD 5.2 Billion in 2025 and is expected to reach USD 6.1 Billion in 2026 and is expected to reach around USD 29.3 Billion by 2035, at a CAGR of 18.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientifi",
        "pubDate": "2026-02-11T08:30:00Z",
        "displayTime": "2026-02-11T08:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891",
          "originalWidth": 2514,
          "originalHeight": 1281,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2CrZC42kgw2SjdY2CY6ucw--~B/aD0xMjgxO3c9MjUxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 2514,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/91DUI4_rVm8Et9pJYV6I4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-cell-therapy-raw-083000732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-cell-therapy-raw-083000732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "TMO"
            },
            {
              "symbol": "MKGAF"
            },
            {
              "symbol": "DHR"
            },
            {
              "symbol": "SDMHF"
            },
            {
              "symbol": "GRFS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]